$ENTA
ENANTA PHARMACEUTICALS INC

2024 Q2 Form 10-Q Financial Statement

#000095017024055581 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $17.97M $17.05M
YoY Change -4.88% -4.16%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.41M $14.24M
YoY Change 6.31% 3.32%
% of Gross Profit
Research & Development $28.74M $35.59M
YoY Change -33.14% -18.14%
% of Gross Profit
Depreciation & Amortization $594.0K $621.0K
YoY Change -8.76% 15.0%
% of Gross Profit
Operating Expenses $28.74M $35.59M
YoY Change -48.31% -18.14%
Operating Profit -$24.19M -$32.77M
YoY Change -34.12% -16.95%
Interest Expense $2.355M $2.563M
YoY Change 26.0% 39.52%
% of Operating Profit
Other Income/Expense, Net $1.132M $1.246M
YoY Change -39.43% -32.17%
Pretax Income -$23.05M -$31.52M
YoY Change -33.84% -16.2%
Income Tax -$395.0K -$363.0K
% Of Pretax Income
Net Earnings -$22.66M -$31.16M
YoY Change -42.0% -17.26%
Net Earnings / Revenue -126.08% -182.7%
Basic Earnings Per Share -$1.07 -$1.47
Diluted Earnings Per Share -$1.07 -$1.47
COMMON SHARES
Basic Shares Outstanding 21.18M 21.16M
Diluted Shares Outstanding 21.18M 21.17M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $230.1M $300.3M
YoY Change -40.48% 42.95%
Cash & Equivalents $35.78M $63.54M
Short-Term Investments $194.3M $236.8M
Other Short-Term Assets $15.87M $10.93M
YoY Change -7.05% -24.52%
Inventory
Prepaid Expenses
Receivables $8.176M $7.756M
Other Receivables $32.46M $32.03M
Total Short-Term Assets $286.6M $351.0M
YoY Change -36.1% 29.47%
LONG-TERM ASSETS
Property, Plant & Equipment $25.05M $15.48M
YoY Change -30.38% 40.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $42.51M
YoY Change 617.59%
Other Assets $105.0K $187.0K
YoY Change -97.81% -73.13%
Total Long-Term Assets $112.2M $62.53M
YoY Change 140.32% 13.05%
TOTAL ASSETS
Total Short-Term Assets $286.6M $351.0M
Total Long-Term Assets $112.2M $62.53M
Total Assets $398.8M $413.6M
YoY Change -19.46% 26.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.68M $6.726M
YoY Change 34.58% -42.81%
Accrued Expenses $12.83M $10.63M
YoY Change -45.55% -31.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $58.23M $54.61M
YoY Change -14.6% 69.77%
LONG-TERM LIABILITIES
Long-Term Debt $1.423M $1.423M
YoY Change 0.0% 0.0%
Other Long-Term Liabilities $227.0K $224.0K
YoY Change -99.88% -45.1%
Total Long-Term Liabilities $227.0K $224.0K
YoY Change -99.88% -45.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $58.23M $54.61M
Total Long-Term Liabilities $227.0K $224.0K
Total Liabilities $249.9M $247.4M
YoY Change -2.89% 333.58%
SHAREHOLDERS EQUITY
Retained Earnings -$294.2M -$271.6M
YoY Change 64.47% 94.22%
Common Stock $443.8M $438.3M
YoY Change 6.12% 6.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $148.9M $166.1M
YoY Change
Total Liabilities & Shareholders Equity $398.8M $413.6M
YoY Change -19.46% 26.69%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$22.66M -$31.16M
YoY Change -42.0% -17.26%
Depreciation, Depletion And Amortization $594.0K $621.0K
YoY Change -8.76% 15.0%
Cash From Operating Activities -$14.78M -$28.60M
YoY Change -54.01% 107.51%
INVESTING ACTIVITIES
Capital Expenditures $6.542M $1.668M
YoY Change 204.14% -30.0%
Acquisitions
YoY Change
Other Investing Activities $197.0K $60.29M
YoY Change -100.14% 22.67%
Cash From Investing Activities -$6.345M $58.62M
YoY Change -95.65% 25.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.647M -6.414M
YoY Change -103.33% 216.43%
NET CHANGE
Cash From Operating Activities -14.78M -28.60M
Cash From Investing Activities -6.345M 58.62M
Cash From Financing Activities -6.647M -6.414M
Net Change In Cash -27.77M 23.61M
YoY Change -226.22% -23.73%
FREE CASH FLOW
Cash From Operating Activities -$14.78M -$28.60M
Capital Expenditures $6.542M $1.668M
Free Cash Flow -$21.32M -$30.27M
YoY Change -37.81% 87.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001177648
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35839
dei Entity Registrant Name
EntityRegistrantName
ENANTA PHARMACEUTICALS, INC
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3205099
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Arsenal Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
607-0800
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
ENTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21179400
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63542000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85388000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
236768000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
284522000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7756000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8614000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10932000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13263000
CY2024Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
32031000
CY2023Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
31004000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
351029000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
422791000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15479000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11919000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42894000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22794000
CY2024Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3968000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
187000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
803000
CY2024Q1 us-gaap Assets
Assets
413557000
CY2023Q3 us-gaap Assets
Assets
462275000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6726000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4097000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10630000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18339000
CY2024Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
33671000
CY2023Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
35076000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3581000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5275000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
54608000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
62787000
CY2024Q1 enta Accrued Royalties Noncurrent
AccruedRoyaltiesNoncurrent
147776000
CY2023Q3 enta Accrued Royalties Noncurrent
AccruedRoyaltiesNoncurrent
159429000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
43412000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21238000
CY2024Q1 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2023Q3 enta Non Convertible Preferred Stock Liabilities
NonConvertiblePreferredStockLiabilities
1423000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
224000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
663000
CY2024Q1 us-gaap Liabilities
Liabilities
247443000
CY2023Q3 us-gaap Liabilities
Liabilities
245540000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21179000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21179000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21059000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21059000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
212000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
211000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
438128000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
424693000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-667000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1174000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271559000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-206995000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
166114000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
216735000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
413557000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462275000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17054000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17795000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35057000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41380000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35585000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43468000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71956000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84370000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14235000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13778000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30753000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26474000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
49820000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
57246000
us-gaap Costs And Expenses
CostsAndExpenses
102709000
us-gaap Costs And Expenses
CostsAndExpenses
110844000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32766000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-39451000
us-gaap Operating Income Loss
OperatingIncomeLoss
-67652000
us-gaap Operating Income Loss
OperatingIncomeLoss
-69464000
CY2024Q1 us-gaap Interest Expense
InterestExpense
2563000
CY2023Q1 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
6004000
us-gaap Interest Expense
InterestExpense
0
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3809000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1837000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8107000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2830000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1246000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1837000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2103000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2830000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31520000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37614000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65549000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66634000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-363000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-985000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37658000
us-gaap Net Income Loss
NetIncomeLoss
-64564000
us-gaap Net Income Loss
NetIncomeLoss
-66644000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.47
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.47
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.79
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.19
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21167000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21167000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21035000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21035000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21128000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21128000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20882000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20882000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31157000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37658000
us-gaap Net Income Loss
NetIncomeLoss
-64564000
us-gaap Net Income Loss
NetIncomeLoss
-66644000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-133000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
860000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
507000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1909000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-133000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
860000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
507000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1909000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31290000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36798000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64057000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64735000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
216735000
CY2023Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-183000
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8099000
CY2023Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
640000
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-33407000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
191884000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2024Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-92000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5561000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-133000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-31157000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
166114000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
321334000
CY2022Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1126000
CY2022Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-825000
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7139000
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1049000
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-28986000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
300837000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
882000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-2909000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7363000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
860000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-37658000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
269375000
us-gaap Profit Loss
ProfitLoss
-64564000
us-gaap Profit Loss
ProfitLoss
-66644000
us-gaap Share Based Compensation
ShareBasedCompensation
13660000
us-gaap Share Based Compensation
ShareBasedCompensation
14502000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1263000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1051000
enta Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
-531000
enta Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
0
enta Payments For Royalty Liabilities
PaymentsForRoyaltyLiabilities
-1013000
enta Payments For Royalty Liabilities
PaymentsForRoyaltyLiabilities
0
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
0
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
42000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-299000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1345000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-7000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-858000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2523000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2331000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1039000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1027000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
56000
enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-2517000
enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1891000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-616000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
261000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5963000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-7709000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-6052000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2137000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-137000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-439000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-46000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53589000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49424000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
212134000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
90627000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
260096000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
176500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2455000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5539000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45507000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
80334000
enta Payments On Royalty Sale Liability Net Of Imputed Interest
PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest
13540000
enta Payments On Royalty Sale Liability Net Of Imputed Interest
PaymentsOnRoyaltySaleLiabilityNetOfImputedInterest
0
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
275000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3734000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
51000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2008000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13764000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1726000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21846000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29184000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
89356000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47962000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67510000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77146000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2792000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1611000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22617000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2870000
us-gaap Interest Paid Net
InterestPaidNet
6575000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Year Founded
YearFounded
1995
us-gaap Net Income Loss
NetIncomeLoss
-64564000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-133816000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-271559000
CY2024Q1 enta Cash Cash Equivalents Short Term And Long Term Marketable Securities
CashCashEquivalentsShortTermAndLongTermMarketableSecurities
300310000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, management’s judgments with respect to its revenue arrangements; liability related to the sale of future royalties; valuation of stock-based awards and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.</span></p>
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
300040000
CY2024Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
369634000
CY2023Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1423000
CY2023Q1 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2024Q1 enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
237051000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
285000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
236768000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
285312000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
12000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
802000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
284522000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3547000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1632000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2967000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7037000
CY2024Q1 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
1529000
CY2023Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6120000
CY2024Q1 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
1515000
CY2023Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
3083000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1072000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
467000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10630000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18339000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4365000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
52.68
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M24D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1196000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.54
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
6000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
318000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
39.18
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5237000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
43.7
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9273000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5237000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
43.7
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9273000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3229000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
52.51
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y1M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
523000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5561000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7363000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13660000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14502000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5561000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7363000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13660000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14502000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
52286
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y1M6D
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-985000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3289000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8158000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8467000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8721000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8983000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
59191000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
96809000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
34763000
CY2024Q1 enta Tenant Improvement Allowance
TenantImprovementAllowance
-15053000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
46993000
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-055581-index-headers.html Edgar Link pending
0000950170-24-055581-index.html Edgar Link pending
0000950170-24-055581.txt Edgar Link pending
0000950170-24-055581-xbrl.zip Edgar Link pending
enta-20240331.htm Edgar Link pending
enta-20240331.xsd Edgar Link pending
enta-ex10_2.htm Edgar Link pending
enta-ex31_1.htm Edgar Link pending
enta-ex31_2.htm Edgar Link pending
enta-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img216959928_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
enta-20240331_htm.xml Edgar Link completed
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable